Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





Mutated Coronavirus in US and Europe 10 Times More Contagious Than Original Strain

By HospiMedica International staff writers
Posted on 01 Jul 2020
A tiny genetic mutation in the SARS coronavirus 2 variant circulating throughout Europe and the US has significantly increased the virus’ ability to infect cells.

Lab experiments performed at The Scripps Research Institute (Jupiter, FL, USA) have shown that viruses with the mutation were much more infectious than those without the mutation in the cell culture system used by the researchers. More...
The mutation had the effect of markedly increasing the number of functional spikes on the viral surface that allow the virus to bind to and infect cells. The spikes give the coronavirus its crown-like appearance and enable it to latch onto target cell receptors called ACE2. The mutation, called D614G, provides greater flexibility to the spike’s “backbone” as more flexible spikes allow newly made viral particles to navigate the journey from producer cell to target cell fully intact, with less tendency to fall apart prematurely. The SARS-CoV-2 variant that circulated in the earliest regional outbreaks lacked the D614G mutation now dominating in much of the world, making it about 10 times more infectious than the strain that originally was identified in Asia.

However, the researchers currently do not know whether this small mutation affects the severity of symptoms of infected people, or increases mortality. Additionally, the researchers who performed their biochemical experiments using harmless viruses engineered to produce key coronavirus proteins found that immune factors from the serum of infected people work equally well against engineered viruses both with and without the D614G mutation. This raises hopes that vaccine candidates in development will work against coronavirus variants with or without that mutation.

“Viruses with this mutation were much more infectious than those without the mutation in the cell culture system we used,” said Scripps Research virologist Hyeryun Choe, PhD, senior author of the study. “The number or density of functional spikes on the virus is four or five times greater due to this mutation. Our data are very clear, the virus becomes much more stable with the mutation.”

Related Links:
The Scripps Research Institute


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Emergency Ventilator
Shangrila935
IV Therapy Cart
Avalo I.V Therapy Cart
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.